Life Sciences

  • November 02, 2026

    Kirkland ITC Patent Litigator Leaves For Wolf Greenfield In DC

    Wolf Greenfield & Sacks PC has expanded its litigation team in Washington, D.C., with a U.S. International Trade Commission-focused intellectual property specialist from Kirkland & Ellis LLP, the firm announced Monday.

  • November 02, 2026

    4 Mass. Rulings You May Have Missed In October

    A nonprofit municipal insurance group is responsible for a portion of a settlement with a man who spent 37 years in prison for a murder he didn't commit, and a biotech startup can continue to pursue trade secrets and breach of contract claims against two former employees and a rival they joined last year, Massachusetts Superior Court judges said in rulings last month. 

  • November 02, 2026

    Pharmacy Hit With NJ Suit Over GLP-1 Marketing

    A compounding pharmacy deceptively and falsely marketed its GLP-1 compounded weight loss medications as safe, effective, clinically supported and personalized, according to a proposed class action filed in New Jersey federal court.

  • November 02, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court last week allowed a stockholder claim over R1 RCM Inc.'s $8.9 billion buyout to proceed, while investors in Meta Platforms Inc. sued to block a stock restructuring they say would let CEO Mark Zuckerberg sell billions of dollars in shares without giving up control of the company.

  • November 02, 2026

    Cancer Therapy Co. Karyopharm Hits Ch. 11 With Merger Plan

    Pharmaceutical company Karyopharm Therapeutics Inc. on Monday filed for Chapter 11 protection in a Texas bankruptcy court with $441.5 million in debt and a plan to merge with biotechnology firm Ayrmid Ltd.

  • October 30, 2026

    Law360 MVP Awards Go To Top Attorneys From 89 Firms

    The lawyers chosen as Law360's 2026 MVPs stand out from their peers by notching significant achievements in high-stakes litigation, complex global matters and record-setting transactions.

  • October 30, 2026

    Teva, AbbVie To Face Trial Over Niaspan Pay-For-Delay Claims

    Long-running multidistrict litigation over AbbVie and Teva Pharmaceuticals' agreement to delay generic forms of cholesterol drug Niaspan is headed toward trial, after a Pennsylvania federal judge Friday found a genuine dispute over whether their agreement was a pay-to-delay settlement that violated antitrust laws.

  • October 30, 2026

    'Why Would I Deceive You?': Fact-Checking The Holmes Doc

    With former Theranos CEO Elizabeth Holmes' criminal case receiving renewed attention following the recent release of Nathan Fielder and Lance Oppenheim's documentary "You Can See Everything," Law360 answers questions about Holmes' 2022 securities fraud conviction and fact-checks some of the documentary's most talked-about moments.

  • October 30, 2026

    States Say Trump Can't Limit Funding Freeze Injunction

    A coalition of 23 states and the District of Columbia urged a Rhode Island federal court Friday to let them continue challenging a now-rescinded Trump administration directive to "temporarily" withhold their federal funding, arguing a permanent injunction should still be on the table.

  • October 30, 2026

    Massachusetts And Idaho To Vote On Restricting Cannabis

    On Tuesday, voters in Massachusetts and Idaho will consider ballot measures that would roll back or restrict marijuana legalization, marking the first time that all statewide ballot questions on the issue of cannabis are geared toward fighting reform.

  • October 30, 2026

    DEA Begins Registering Hundreds Of Marijuana Dispensaries

    The U.S. Drug Enforcement Administration began registration of more than 900 state-licensed medical marijuana dispensaries across seven states, according to an announcement on Friday by the U.S. Department of Justice, which said applications for manufacturers and distributors would likely require additional review.

  • October 30, 2026

    Pharma Supplier Sues To Undo $52M Minority Stake Deal

    Pharmaceutical ingredient manufacturer Pfanstiehl Holdings Inc. has sued a minority shareholder and its general partner in the Delaware Chancery Court, seeking to unwind a $52.3 million transaction that allegedly transferred a majority economic interest in the shareholder's stake to an unidentified investor without required notice or consent.

  • October 30, 2026

    AGs Seek Final OK For $29.6M Glenmark Price-Fixing Deal

    A coalition of 48 states and territories is asking a Connecticut federal judge to give his final approval to a $29.6 million settlement with Glenmark Pharmaceuticals Ltd. that would end claims that the drugmaker conspired with competitors to inflate prices and allocate markets for generic drugs.

  • October 30, 2026

    Ohio Judge Strikes Down Remainder Of 6-Week Abortion Ban

    An Ohio state judge permanently blocked provisions of the state's "heartbeat law" that were previously under review after the court found that the bill's main feature — its prohibition on abortion after around six weeks of pregnancy — violated the state's constitution.

  • October 30, 2026

    3 Firms Guide Pair Of Biotech IPOs Raising $310M

    Two biotechnology firms began trading on Friday after raising a combined $310 million in their initial public offerings, marking the latest in a wave of biotechs to hit the public markets.

  • October 30, 2026

    $9.1M Fee Award Against ChromaDex Erased By Fed. Circ.

    The Federal Circuit Friday overturned a $9.1 million attorney fee award issued to Elysium Health Inc. stemming from a patent infringement case brought by ChromaDex and Dartmouth College, ruling that a district judge had not gone far enough in his patent eligibility analysis.

  • October 30, 2026

    Botox Exempt From Medicare Price Talks, Judge Rules

    The Centers for Medicare & Medicaid Services can't subject AbbVie's Botox to Medicare price negotiations under the Inflation Reduction Act, a D.C. federal judge held, finding CMS misinterpreted an IRA exclusion concerning biological products derived from human plasma.

  • October 30, 2026

    Judge Won't Free Pierce Atwood Of Investor's Malpractice Suit

    Pierce Atwood LLP failed to win dismissal of a lawsuit from a Ukrainian oligarch who says the firm's advice led to a $1.85 million judgment against him in investor litigation over the liquidation of now-insolvent genetic testing company Pathway Genomics Corp.

  • October 29, 2026

    Judge 'Put Off' By Atty Fee Bid In $59.5M Menstrual App Deal

    A California federal judge said Thursday that he'll give final approval to a $59.5 million settlement resolving class claims over a menstrual tracking app sharing sensitive health data with Google, but he cut the $19 million attorney fee request by 5%, saying counsel is "taking money out of consumers' pockets."

  • October 29, 2026

    Colo. Justices Won't Review Hospital's Injunction Compliance

    The Colorado Supreme Court declined Thursday to take up transgender youth patients' challenge to a Denver judge's ruling that discharged their contempt citation against Children's Hospital Colorado for not resuming providing medical gender-affirming care to transgender adolescents.

  • October 29, 2026

    Fertility Cos. Accused Of Moving Eggs Without Consent

    A national fertility clinic network has been hit with a suit in Los Angeles Superior Court alleging it jeopardized a 50-year-old woman's ability to have a biological child by transporting her frozen eggs across state lines to an automated facility without her permission.

  • October 29, 2026

    Camp Lejeune Plaintiffs Blast 'Absurd' Lone Pine Motion

    Plaintiffs in massive multidistrict litigation over toxic water at the Camp Lejeune military base are urging a North Carolina federal court to reject the federal government's bid for a Lone Pine motion requiring claimants to submit proof of their claims, saying it would delay the litigation by years, if not decades, and cause the plaintiffs' costs to skyrocket.

  • October 29, 2026

    Delaware Chancery Keeps $8.9B R1 RCM Buyout Claim Alive

    The Delaware Chancery Court has ruled that private equity firm TowerBrook Capital Partners LP and health system Ascension Health Alliance must face a stockholder claim challenging healthcare revenue management venture R1 RCM Inc.'s $8.9 billion take-private deal, finding that their joint investment vehicle qualified as a controlling stockholder despite owning less than one-third of the company's voting shares.

  • October 29, 2026

    DOL Finalizes Pharmacy Benefit Manager Fee Disclosure Rule

    The U.S. Department of Labor's employee benefits arm unveiled a final rule Thursday that requires pharmacy benefit managers — which act as intermediaries between drugmakers, pharmacies and insurers — to make new disclosures on their fees and compensation to employer-sponsored group health plans.

  • October 28, 2026

    Product Liability's Regulatory & Legislative Recap So Far

    Over the summer and early fall, lawmakers proposed measures aimed at putting safeguards around the rapidly growing industry of artificial intelligence, as public concerns over its safety climb in tandem. The new nominee to head the U.S. Food and Drug Administration also faced sharp queries over her views on vaccines and birth control.

Expert Analysis

  • 6th Circ. Spotlights Cannabis Contract Enforceability Risks

    Author Photo

    The Sixth Circuit's recent reversal of a $31.8 million jury verdict against a subsidiary of cannabis giant Curaleaf highlights that state licenses do not necessarily provide the legal foundation needed to enforce contracts in federal court, which is a pattern that appears across many sectors, say attorneys at ArentFox Schiff.

  • Where DOJ's Fraud Directive May Actually Affect Enforcement

    Author Photo

    The U.S. Department of Justice’s recent directive outlining corporate fraud enforcement priorities is mostly a management document instead of a policy, but one part may actually undermine the directive's goals by leading to worse outcomes for organizational defendants and less corporate self-disclosure, says Zachary Warren at Williams & Connolly.

  • Why Vaccine Court Inoculates Drugmakers Against Litigation

    Author Photo

    Most claimants alleging injuries from routine childhood vaccines must complete an administrative compensation proceeding before they can sue in civil court — and recent legislative efforts aimed at weakening vaccine manufacturers' legal protections do not account for the important reasons the existing framework was put in place, say attorneys at Goldman Ismail.

  • What Lawyers Should Know Before Accepting Crypto Payment

    Author Photo

    As clients increasingly request to pay legal fees, retainers and escrow funds using cryptocurrency, lawyers should consider how only a handful of state bar authorities have addressed the issue with varying ethics opinions, as well as the related questions that no authority has yet answered, says attorney Felix Shipkevich.

  • What To Know As State 'Neural Data' Privacy Laws Emerge

    Author Photo

    Attorneys at Goodwin discuss new state laws aimed at regulating consumer data generated from nervous system activity, explain why neurotechnology is attracting state and federal legislators’ attention, and highlight the compliance obligations that industry players should address now.

  • Data Sale In Spirit Bankruptcy Raises Novel Privacy Risks

    Author Photo

    Spirit Airlines' planned sale of deidentified business data to Google for artificial intelligence training exposes gaps in the Bankruptcy Code's privacy guardrails, particularly for employee information, say attorneys at Patterson Belknap.

  • IDScan Data Breach Puts Spotlight On Vendor Oversight

    Author Photo

    A recently reported breach that exposed millions of identification documents held by IDScan.net highlights the liability risks for businesses that contract with third-party identity processors, and emphasizes the importance of auditing vendors' data retention practices, say attorneys at Tucker Ellis.

  • Series

    Mentalism Makes Me A Better Lawyer

    Author Photo

    Convincing strangers I can read their minds may seem like an unusual second career for a legal practitioner, but both disciplines share several important requirements, including trust and preparation, says Warren Biro at Manatt.

  • Why And How To Build A Neurodiversity-Informed Practice

    Author Photo

    By better understanding neurodiversity and implementing simple accommodations for clients with autism, ADHD or learning differences, attorneys can build stronger relationships with those who may otherwise struggle to obtain and benefit from legal services, while developing good habits that will benefit everyone they represent, says Ting Cheung at Sanford Heisler.

  • Opinion

    PTAB Panels Should Revamp Their IPR Merits Decisions

    Author Photo

    In light of U.S. Patent and Trademark Office Director John Squires' recent announcement about returning merits institution determinations to the Patent Trial and Appeal Board, the implementing framework should strengthen PTAB panels' responsibility for the benefit of both petitioners and patent owners, says Brandon Theiss at AddyHart.

  • Patent Eligibility Bulletin: Claim Solutions, Not Results

    Author Photo

    In the third quarter of the year, two Federal Circuit decisions illustrated that claims sharing the same disclosure can fall on opposite sides of the patent eligibility line, depending on the specific nuances of tech patents' claims, says Reilley Keane at Banner Witcoff.

  • Abbott FCA Deal Shows Enforcement Adequacy Quandaries

    Author Photo

    Abbott Laboratories’ recent False Claims Act resolution illustrates several tricky questions that both prosecutors and defense counsel must address when weighing whether a civil enforcement action alone adequately addresses allegedly wrongful conduct, says James Koukios at MoFo.

  • New DNA Screening Standard Has No Clear Playbook

    Author Photo

    Although the government has not yet released promised guidance intended to support its new standards for screening mail-order DNA, companies should not read this as a reprieve from the Oct. 13 compliance deadline because the delay shifts enforcement risk to statutes that need no new authority, including false statements, the False Claims Act and fraud, says Ashwin Ram at Buchalter.

  • Series

    Mich. Banking Brief: All The Notable Legal Updates In Q3

    Author Photo

    We are at an inflection point for Michigan financial services law, with a state Supreme Court decision recently overruling more than 25 years of precedent on the Michigan Consumer Protection Act, and pending legislation that could significantly shift the regulatory landscape, say attorneys and advisers at Dykema.

  • Testing AI's Promise For Large-Scale Document Review

    Author Photo

    Our document-review comparison of attorneys' responsiveness and issue coding decisions versus predictions generated by artificial intelligence across 1,600 documents suggests that these tools can offer a reasonable and reliable basis for improved discovery workflows, provided lawyers understand where guardrails are needed, say attorneys at Redgrave.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.